Xcout Intelセルシード competitors & alternatives
The 12 closest competitors and alternatives to セルシード among biotech companies — ranked by similarity to what セルシード actually does, not by market-cap band.
Subscribe to see セルシード’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About セルシード
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
セルシード at a glance
セルシード is a biotech company headquartered in Tokyo, Japan. It is publicly listed (7776) with a market capitalisation of $58.1M.
Top 12 セルシード competitors
Ranked by semantic similarity — how close each company is to セルシード by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
Similar biotech company
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-based, and cell processing products. Furthermore, it offers contract development and manufacturing services, alongside expert consulting. The company, which was incorporated in 2017 and is based in Tokyo, Japan, previously operated under the name Cuore Inc. before adopting Cuorips Inc. in June 2017.
Similar biotech company
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnishes comprehensive support for immuno-cell therapy, encompassing critical elements such as specialized technical expertise, advanced facilities, robust operational systems, essential materials, and skilled cell engineers. Furthermore, MEDINET actively manufactures regenerative medical products, investigational cell products, and other specified cell-based therapies. Its extensive value chain offerings also cover personnel training, facility and equipment design, operational management, standard operating procedure (SOP) preparation, logistics networks, information systems, purchasing and production management, stringent quality management and assurance, and technology transfer and process development. The firm actively collaborates with and supports medical institutions, research organizations, and biopharmaceutical companies in their endeavors to advance immuno-cell therapy.
Similar biotech company
CO.DON is a biopharmaceutical company specializing in tissue engineering and the development and manufacturing of personalized cell therapies. The company provides regenerative treatments for joint cartilage defects to medical professionals and patients.
Similar biotech company
Pharmicell develops and provides stem cell therapeutics, cell culture media, and biomedical products, alongside chemical raw materials and advanced industrial materials such as nucleosides and medical PEGs. The company serves patients, researchers, and medical institutions by offering stem cell-based treatments, contract development and manufacturing (CDMO) services, and stem cell-derived cosmetics.
Similar biotech company
ThermoGenesis Group, Inc. develops and commercializes automated cell processing systems, devices, and CDMO services for the cell and gene therapy industry. The company provides closed-system solutions for clinical biobanking, cellular processing, and manufacturing to support researchers, clinicians, and biomanufacturing organizations.
Similar biotech company
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and testing. In addition, the company is involved in commercialization of its proprietary platform technology for biologics development; development, manufacture, and sale of manufacture ancillary materials, such as RetroNectin that is used in the manufacture of gene therapy product; application for marketing authorization of NY-ESO-1 siTCR gene therapy product; and development of JAK/STAT technology suitable for CAR gene therapy and applied development of CereAAV, a brain-tropic adeno-associated virus vector. It provides its products and services through sales agents or directly to its customers. The company was incorporated in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
Similar biotech company
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Biotechnology
Shenzhen Cellbri Bio-Innovation Technology, founded in 2020 and headquartered in Shenzhen, develops and manufactures scalable solutions and closed-loop systems for the cell and gene therapy industry.
Similar biotech company
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products derived from its proprietary human parthenogenetic stem cells, a unique form of pluripotent stem cells. ISCO is actively engaged in developing specialized cell types, such as neural stem cells, which hold promise for treating Parkinson's disease and other disorders affecting the central nervous system. Beyond therapeutics, the company also develops, manufactures, and commercializes anti-aging skincare products and an extensive range of human cell culture products. Its diverse portfolio of human cell culture products serves as vital research tools across numerous scientific disciplines. This includes specialized cells and reagents designed for studying: Dermatology: Skin diseases, toxicology, and wound healing. Cardiovascular & Oncology: Heart and blood vessel conditions, and various cancers. Respiratory: Bronchial and tracheal conditions, toxicity, cystic fibrosis, asthma, and pathogenesis. Reproductive & Urological: Prostate, renal, bladder, corneal, and female reproductive system diseases, as well as general cellular physiology. Musculoskeletal & Metabolic: Skeletal muscle biology, diabetes, insulin pathways, muscle repair, and myotube development. The company also provides adult stem cells for regenerative medicine research and a full complement of reagents and supplements essential for cell growth, staining, and cryopreservation. Distribution of ISCO's skincare range occurs via its website and specialized professional channels, while its human cell culture products reach customers through a dedicated sales force, original equipment manufacturer (OEM) partners, and authorized brand distributors. Established in 2001, International Stem Cell Corporation maintains its headquarters in San Diego, California.
Biotechnology
iOrganBio is a biotechnology company founded in 2024 that develops AI-powered platforms for the precision engineering and manufacturing of human cells and organoids. The company's CellForge platform aims to create reproducible human cell models for research applications, including cardiac disease studies and biological simulation.
Biotechnology
AcroCyte Therapeutics, Inc. is a biotechnology company dedicated to overcoming common laboratory challenges through its proprietary R³CE rapid, reproducible, rare cell 3D expansion technology. Recognized with awards such as the Taiwan National Innovation Award, the company focuses on advancing biomedical research and cell-based applications.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of セルシード and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for セルシードand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →